Here are some reasons it may have gapped Down: 1) Regulatory Concerns: A recent announcement from the Ministry of Health in China regarding stricter import regulations for nutritional supplements, a key product category for ZBAO, may have caused investor concern. 2) Supply Chain Disruptions: Potential disruptions in the supply of key ingredients due to recent weather events in a major...
Continue reading >>
If you're an investor in CLIK, you're probably feeling elated today. The stock has skyrocketed by 18.2% on 18.5M volume, leaving many wondering what's driving this sudden surge. In this article, we'll delve into the reasons behind the gap up and examine the recent news events that may have contributed to this remarkable gain. Table of Contents Reason 1: Positive Phase 3 Clinical Trial...
Continue reading >>
If you're a shareholder of ARBB, you're probably feeling optimistic today. The stock has moved by 18.7% on 14.5M volume, leaving many investors wondering what's behind the sudden surge. In this article, we'll explore the reasons behind the market move and examine the recent news events that may have contributed to this increase. Table of Contents Potential Acquisition Announcement/Positive...
Continue reading >>
The whipsaw action this week has been incredible to watch (and trade) as the bears and bulls try to establish key support and resistance levels ahead of the first-quarter earnings season. Tariff news has been the center of attention but that subject could move to the back burner as over 70 countries will now be negotiating with the US for new trade deals. The technical outlook remains...
Continue reading >>
Galmed Pharmaceuticals Soars 18.7% on Positive Clinical Trial Results: What's Next? If you're a shareholder of Galmed Pharmaceuticals Ltd. (GLMD), you're probably celebrating today. The biotechnology company's stock has moved by 18.7% on 14.2M volume, following the announcement of positive topline results from its Phase 3 clinical trial of Aramchol for the treatment of non-alcoholic...
Continue reading >>
FMTO (FMTO) Surges 18.2% on 14.5M Volume If you're a shareholder of FMTO, you're probably celebrating today. The biotechnology company's stock has moved by 18.2% on 14.5M volume, following the announcement of FDA approval for its lead drug, NeuroBoost. In this article, we'll explore the reasons behind the surge and examine the recent news events that may have contributed to this increase. Table...
Continue reading >>